Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.40 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12750442 | 0.87 | FFAR4 (0.43) | PTGER1CYP2C9MCL1TAAR1FFAR4 | |
| SCHEMBL8532352 | 0.84 | PPARG (0.40) | PTGER1CYP2C9MCL1FFAR4POLB | |
| SCHEMBL8523314 | 0.83 | POLB (0.46) | PTGER1CYP2C9MCL1FFAR4POLB | |
| SCHEMBL26601818 | 0.79 | PTGER1 (0.47) | PTGER1CYP2C9MCL1TAAR1 | |
| SCHEMBL26601663 | 0.76 | MCL1 (0.51) | PTGER1MCL1MRGPRX4BAK1FOLH1 | |
| SCHEMBL31518041 | 0.76 | MCL1 (0.51) | PTGER1MCL1MRGPRX4BAK1FOLH1 | |
| SCHEMBL9204010 | 0.76 | RXRA (0.48) | PTGER1MRGPRX4FOLH1 | |
| SCHEMBL31517882 | 0.75 | CA9 (0.49) | PTGER1CYP2C9MCL1FFAR4MRGPRX4 | |
| SCHEMBL26601691 | 0.75 | MCL1 (0.47) | PTGER1MCL1FFAR4MRGPRX4BAK1 | |
| SCHEMBL31336208 | 0.75 | RAB9A (0.50) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2016-05-26 | — | — | US | disclosed |
| EP-2455381-B9 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2455381-B1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-2455381-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | Japan Tobacco, Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | PTGER1 1511/4885CYP2C9 1058/4885MCL1 891/4885 |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | PTGER1 1511/4885CYP2C9 1058/4885MCL1 891/4885 |
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | PTGER1 1511/4885CYP2C9 1058/4885MCL1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.